The Cooper Companies, Inc. (NASDAQ:COO) Receives $110.25 Average Target Price from Analysts

Shares of The Cooper Companies, Inc. (NASDAQ:COO) have received a consensus rating of “Moderate Buy” from the ten brokerages that are covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $110.25.

Several research analysts have recently commented on the company. Morgan Stanley reduced their price target on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating for the company in a research report on Friday, December 6th. BNP Paribas raised shares of Cooper Companies to a “hold” rating in a research report on Thursday, March 13th. JPMorgan Chase & Co. decreased their target price on shares of Cooper Companies from $120.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. StockNews.com lowered Cooper Companies from a “buy” rating to a “hold” rating in a report on Wednesday, December 11th. Finally, Robert W. Baird reduced their target price on Cooper Companies from $117.00 to $107.00 and set an “outperform” rating on the stock in a research report on Friday, March 7th.

Cooper Companies Stock Up 1.3 %

NASDAQ:COO opened at $84.98 on Tuesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12. The firm has a market cap of $16.99 billion, a PE ratio of 43.58, a price-to-earnings-growth ratio of 2.25 and a beta of 1.02. The company has a 50-day moving average of $89.52 and a 200 day moving average of $97.53. Cooper Companies has a 1-year low of $77.05 and a 1-year high of $112.38.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.92. The firm had revenue of $964.70 million for the quarter, compared to the consensus estimate of $981.25 million. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. As a group, research analysts anticipate that Cooper Companies will post 3.98 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Byrne Asset Management LLC acquired a new position in Cooper Companies during the fourth quarter valued at $33,000. OFI Invest Asset Management acquired a new position in shares of Cooper Companies in the 4th quarter valued at about $34,000. New Age Alpha Advisors LLC purchased a new stake in shares of Cooper Companies in the fourth quarter worth about $38,000. Brown Brothers Harriman & Co. grew its holdings in Cooper Companies by 191.0% during the third quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock worth $46,000 after acquiring an additional 275 shares during the period. Finally, Covestor Ltd grew its holdings in Cooper Companies by 35.5% during the fourth quarter. Covestor Ltd now owns 458 shares of the medical device company’s stock worth $42,000 after acquiring an additional 120 shares during the period. 24.39% of the stock is owned by institutional investors and hedge funds.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.